# byoRNA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/byorna

- Industry: Biotechnology
- Headquarters: Pessac, France
- Website: www.byorna.bio
- Total disclosed funding: $1.8M
- Latest round: Seed (Jul 1, 2025)
- Investors on record: 2

## About

Based in France, byoRNA SAS specializes in developing messenger RNA (mRNA) through innovative bioproduction technology, enabling cost-effective solutions for therapeutic applications in pharmaceutical and biotechnology sectors.byoRNA SAS, founded in 2022 in Pessac, France, focuses on the design and implementation of bioproduction platforms for mRNA production. The company recently secured EUR 1.5 mn in funding led by Polytechnique Ventures, with participation from Irdi Capital Investissement. The latest funding round occurred on July 1, 2025, and represents the total amount raised to date. The firm has successfully completed one deal.ByoRNA specializes in the production of high-quality messenger RNA (mRNA) using proprietary bioproduction technology. Their offerings include designing and implementing bioproduction platforms that utilize eukaryotic cell biofactories to produce mRNA at lower costs compared to traditional methods. The technology allows for the extraction of highly purified therapeutic mRNA, addressing health challenges such as infectious diseases, cancer, and rare genetic disorders. ByoRNA's products target pharmaceutical and biotechnology companies in North America, Europe, and Asia, where demand for mRNA solutions is growing.ByoRNA generates revenue through partnerships with pharmaceutical and biotech companies seeking to utilize its mRNA production technology for therapeutic development. The transaction structure focuses on B2B collaborations, optimizing mRNA expression tailored to client needs. Revenue comes from contracts that include milestone payments and royalties based on the commercialization of mRNA-based therapies developed with their platform.ByoRNA plans to use the EUR 1.5 mn raised in July 2025 to finalize its molecular design and production platforms and conduct preclinical testing of its RNA in animal models. The company aims to expand into new markets across North America, Europe, and Asia by launching new products that address critical health challenges, enhancing its role in the mRNA landscape.

## Funding rounds

- Seed, Jul 1, 2025, $1.8M — Irdi Capital Investissement, Polytechnique Ventures

## Investors

- Irdi Capital Investissement (https://capitalatlas.ai/funds/irdi-capital-investissement) — Seed
- Polytechnique Ventures (https://capitalatlas.ai/funds/polytechnique-ventures) — Seed